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Objective: To perform two scoping systematic reviews of the literature on cytokine mea-
surement in cerebral microdialysis (CMD) and cerebrospinal fluid (CSF) in aneurysmal 
subarachnoid hemorrhage (SAH) patients, aiming to summarize the evidence relating 
cytokine levels to pathophysiology, disease progression, and outcome.
Methods: Two separate systematic reviews were conducted: one for CMD cytokines 
and the second for CSF cytokines.
Data sources: Articles from MEDLINE, BIOSIS, EMBASE, Global Health, Scopus, 
Cochrane Library (inception to October 2016), reference lists of relevant articles, and 
gray literature were searched.
Study selection: Two reviewers independently identified all manuscripts utilizing pre-
defined inclusion/exclusion criteria. A two-tier filter of references was conducted.
Data extraction: Patient demographic and study data were extracted to tables.
Results: There were 9 studies identified describing the analysis of cytokines via CMD 
in 246 aneurysmal SAH patients. Similarly, 20 studies were identified describing the 
analysis of CSF cytokines in 630 patients. The two scoping systematic reviews demon-
strated the following: (1) limited literature available on CMD cytokine measurement in 
aneurysmal SAH with some preliminary data supporting feasibility of measurement and 
potential association between interleukin (IL)-6 and patient outcome. (2) Various CSF 
measured cytokines may be associated with patient outcome at 3–6 months, including 
IL-1ra, IL-6, IL-8, and tumor necrosis factor-alpha. (3) There is a small literature body 
supporting an association between acute/subacute CSF transforming growth factor 
levels and the development of chronic hydrocephalus at 2–3 months.
Conclusion: The evaluation of CMD and CSF cytokines is an emerging area of the 
literature in aneurysmal SAH. Further large prospective multicenter studies on cytokines 
in CMD and CSF need to be conducted.
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iNTRODUCTiON
Inflammation in the setting of aneurysmal subarachnoid hem­
orrhage (SAH) is believed to be a potential driver of many 
secondary insults in this often critically ill population (1–4). As 
with animal models of stroke, inflammatory mediators have been 
associated with loss of salvageable ischemic penumbra, infarct 
propagation, and cerebral edema (5–8). It has been proposed that 
various inflammatory cytokines are associated with secondary 
injury and pathological processes post­aneurysmal SAH (1, 2).
Within the aneurysmal SAH population, numerous studies 
have been published associating serum inflammatory markers 
with patient outcome and the risk of cerebral vasospasm/delayed 
ischemic neurological deficits (DINDs) (1, 3, 4). Furthermore, 
analysis of cerebrospinal fluid (CSF) cytokines has demonstrated 
an association between interleukin (IL)­6 and tumor necrosis 
factor­alpha (TNF­a) with the risk of cerebral vasospasm and 
DIND through an extensive systematic review/meta­analysis of 
the available literature (9). Of note, this systematic review focused 
only on the relationship IL­6 and TNF­a with vasospasm, with­
out any comment or consideration of other important primary 
outcomes such as patient morbidity/mortality.
Aside from the above­mentioned associations, the remain­
ing literature on inflammatory cytokines in aneurysmal SAH is 
scattered and scarce. In particular, the literature on cytokines in 
cerebral microdialysis (CMD) samples from aneurysmal SAH 
patients is very limited (10–18). In addition, apart from the sys­
tematic review on the association between CSF IL­6 and TNF­a 
with vasospasm/DIND (9), there is limited literature on the 
association between CSF cytokines and other relevant endpoints 
(10, 19–37) such as patient functional outcome, neurophysiologic 
outcome, chronic hydrocephalus/ventriculoperitoneal shunt 
(VPS) dependency, and tissue fate.
The goal of this project was to produce a scoping systematic 
review of the literature on both CMD and CSF cytokines in 
aneurysmal SAH. There were two main focuses for this article: 
(1) to provide a comprehensive scoping systematic review of the 
literature on CMD cytokines in aneurysmal SAH; (2) produce 
a scoping systematic review evaluating the association between 
CSF cytokines and the following outcomes (excluding vasos­
pasm/DIND): patient functional outcome, neurophysiologic 
outcome, chronic hydrocephalus/VSP dependency, and tissue 
outcome.
MeTHODS
Two separate scoping systematic reviews were conducted, using 
the methodology outlined in the Cochrane Handbook for 
Systematic Reviewers (38). Data were reported following the 
Preferred Reporting Items for Systematic Reviews and Meta­
Analyses (39). The review questions and search strategy were 
decided upon by the primary author (Frederick A. Zeiler) and 
supervisors (Adel Helmy and David K. Menon).
This article was conducted in concert with a similar review 
on cytokines in CMD and CSF for severe traumatic brain injury 
(TBI) patients, which is currently unpublished and under 
review (40).
Search Question and Population  
of interest
Given that two separate systematic reviews were conducted, one 
for CMD cytokines and the other for CSF­based cytokines, two 
distinct questions were posed. The lack of literature identified 
through a preliminary search of PubMed led us to conduct a 
scoping review for the CMD cytokine search, with the attempt to 
identify all studies in this area to date. The larger literature base 
for CSF cytokines in aneurysmal SAH led us to narrow our ques­
tion for this scoping review, focusing on relevant outcomes (see 
below). The questions posed for this scoping systematic review 
were as follows:
1. What literature has been published on CMD of cytokines in 
aneurysmal SAH?
2. Is there literature to suggest an association between CSF­based 
cytokine measures in aneurysmal SAH and patient outcome, 
chronic hydrocephalus/shunt dependency, neurophysiologic 
outcome, or tissue outcome?
For the CMD cytokine scoping review, all articles describ­
ing microdialysis­based cytokine measures in humans with 
aneurysmal SAH were included to provide a comprehensive 
overview.
For the CSF cytokine review, the primary outcome measures 
of interest were documented association between CSF meas­
ured cytokines and patient outcome, chronic hydrocephalus/
shunt dependency, neurophysiologic outcome (as measured 
via intensive care unit (ICU)­based monitoring, intracranial 
pressure/cerebral perfusion pressure, brain tissue oxygen 
monitoring (PbtO2), thermal diffusion assessment of cerebral 
blood flow (CBF), transcranial Doppler (TCD) measure of 
cerebral blood flow velocity, any neuroimaging­based assess­
ment of CBF/perfusion, and electrophysiology), and tissue 
outcome [as assessed on follow­up neuroimaging by either 
computed tomography (CT) or magnetic resonance imaging]. 
Any outcome score or mention of morbidity/mortality within 
the studies was deemed acceptable for documentation of 
patient outcome. Secondary outcome measures were complica­
tions associated with CSF monitoring of cytokines. Of note, 
cerebral vasospasm and DIND were specifically excluded as a 
primary outcome for the CSF cytokine review given a recently 
conducted systematic review published on this exact relation­
ship (9).
Acceptable cytokines in CMD or CSF included IL­1a, IL­1b, 
IL­1ra, IL­2, sIL­2ra, IL­3, IL­4, IL­5, IL­6, IL­7, IL­8, IL­9, IL­10, 
IL­11, IL­12, IL­12p70, IL­13, IL­14, IL­15, IL­16, IL­17, inducible 
protein­10, eotaxin, TNF, interferon gamma, monocyte chemoat­
tractant proteins (MCP), macrophage inflammatory proteins 
(MIPs), transforming growth factor (TGF), nerve growth factor, 
brain­derived neurotrophic factor, glial­derived neurotrophic 
factor, soluble tumor necrosis factor receptor (sTNFR), granu­
locyte macrophage colony­stimulating factor (GM­CSF), sFAS, 
soluble vascular cell adhesion molecule­1, soluble intracellular 
adhesion molecule­1, platelet­derived growth factor, RANTES, 
macrophage­derived chemokine (MDC), Flt3, fractalkine, and 
fibroblast growth factor receptor.
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inclusion/exclusion Criteria
CMD Cytokine Review
Inclusion criteria: all studies including human subjects with 
aneurysmal SAH, any study size, any age category, CMD analysis 
for cytokines, and mention of any outcome (patient based or 
otherwise; excluding vasospasm/DIND). Exclusion criteria: non­
English studies, only non­cytokine/chemokine inflammasome 
proteins measured, animal studies, non­aneurysmal SAH, and 
unconfirmed/angio­negative SAH.
CSF Cytokine Review
Inclusion criteria were as follows: all studies including human 
subjects with aneurysmal SAH, studies with 10 or more patients, 
any age category, CSF analysis for cytokines, and documentation 
either: patient functional outcome, neurophysiologic outcome, 
or tissue outcome in relation to CSF cytokine measures. 
Exclusion criteria were as follows: non­English studies, only 
non­cytokine/chemokine inflammasome proteins measured, 
animal studies, non­aneurysmal SAH, unconfirmed/angio­
negative SAH, and studies of less than 10 patients. Also excluded 
were studies focused only on the outcome of cerebral vasospasm/
DIND (as this has been explored in a recent systematic review 
and meta­analysis).
Search Strategies
MEDLINE, BIOSIS, EMBASE, Global Health, SCOPUS, and 
Cochrane Library from inception to October 2016 were searched 
using individualized search strategies. The search strategy for the 
CMD scoping systematic review using MEDLINE can be seen 
in Appendix A in Supplementary Material, with a similar search 
strategy utilized for the other databases. Further, the search strat­
egy for the CSF scoping systematic review using MEDLINE can 
be seen in Appendix B in Supplementary Material, with similar 
strategies employed for the other databases.
In addition, we surveyed relevant meeting proceedings for 
the last 5 years looking for ongoing and unpublished work based 
on the cytokine analysis via CMD or CSF in aneurysmal SAH 
patients. We elected to include published meeting proceedings 
to provide as comprehensive of a scoping systematic review as 
possible. It is acknowledged that the quality of evidence derived 
from such pseudopeer­reviewed meeting publications is limited. 
However, given that cytokine research in SAH is relatively 
“new” and our goal was to produce a systematically conducted 
scoping review on the topic, we elected to include them to be 
comprehensive. The meeting proceedings of the following profes­
sional societies were searched: Canadian Neurological Sciences 
Federation, American Association of Neurological Surgeons, 
Congress of Neurological Surgeons, European Neurosurgical 
Society, World Federation of Neurological Surgeons (WFNS), 
American Neurology Association, American Academy of 
Neurology, European Federation of Neurological Science, World 
Congress of Neurology, Society of Critical Care Medicine, 
Neurocritical Care Society, European Society for Intensive Care 
Medicine, World Federation of Societies of Intensive and Critical 
Care Medicine, American Society for Anesthesiologists, World 
Federation of Societies of Anesthesiologist, Australian Society 
of Anesthesiologists, International Anesthesia Research Society, 
Society of Neurosurgical Anesthesiology and Critical Care, Society 
for Neuroscience in Anesthesiology and Critical Care, Japanese 
Society of Neuroanesthesia and Critical Care, and the College of 
Intensive Care Medicine Annual Scientific Meeting (Australia), 
World Stroke Organization, UK Stroke Forum, International 
Stroke Conference, European Stroke Society, Canadian Stroke 
Congress, SMART Stroke Group, and the Australian Stroke 
Society.
Finally, reference lists of any review articles on CSF or CMD 
cytokines were reviewed for any missed relevant studies.
Study Selection
Utilizing two reviewers, a two­step review of all articles returned 
by our search strategies was performed. First, the reviewers inde­
pendently (Frederick A. Zeiler and Eric Peter Thelin) screened 
titles and abstracts of the returned articles to decide if they met 
the inclusion criteria. Second, full text of the chosen articles 
was then assessed to confirm if it met the inclusion criteria and 
that the primary outcome of interest was reported in the studies 
(Frederick A. Zeiler and Eric Peter Thelin). Any discrepancies 
between the two reviewers were resolved by a third reviewer if 
needed (Adel Helmy or David K. Menon).
Data Collection
Data were extracted from the selected articles and stored in an 
electronic database. Data fields included type of study, article 
location, number of patients, patient demographics, aneurysm 
characteristics/treatment, Hunt and Hess (H  +  H) clinical 
grade (41), World Federation of Neurological Surgeons (WFNS) 
clinical grade (42), Fisher CT grade (43), ICU therapies applied, 
CMD/CSF substrate measured, CMD/CSF measurement details 
(probe tissue location and sampling frequency), outcome meas­
ure described (patient, neurophysiologic, and tissue), association 
between CMD/CSF cytokine measure to outcome, and compli­
cations. Complications of interest for the CSF studies were any 
related to ventriculostomy: misplacement, tract hemorrhage, 
infection, and extra­axial hemorrhage/collection formation. All 
data for both the CSF and CMD cytokine studies can be found 
in Tables 1–4.
Bias Assessment
As the goal of this study was to produce a systematically con­
ducted scoping review of the available literature on CMD and 
CSF cytokine measures in aneurysmal SAH, formal bias assess­
ment was not done. Our desire was to produce a comprehensive 
overview of the current literature on the topic of CMD/CSF 
cytokines in aneurysmal SAH. Formal evidence grading was not 
conducted (given the limited and heterogenous literature body), 
and thus, we deemed formal bias risk assessment unnecessary 
for this emerging area of literature, which clearly suffers from 
standard biases associated with new areas of clinical research.
Statistical Analysis
A meta­analysis was not performed in this study due to the 
heterogeneity of data and study design within the articles 
identified.
TABLe 1 | CMD cytokine study characteristics and patient demographics.
Reference Number of 
patients
Study type Article 
location
Mean age 
(years)
Patient characteristics Primary and secondary 
goal of study
Graetz et al. (10) 24 Prospective 
observational
Manuscript 50 years (range: 
43.5–62 years)
aSAH Primary: to evaluate the 
pattern of IL-6 expression in 
CMD, CSF, and serum
Admission WFNS:
I–III in 14
IV–V in 10
Mean Fisher CT Score: 4 (range: 3–4) Secondary: compare IL-6 
expression to ICP, CMD-
defined ischemia (LPR > 30, 
glycerol > 80 μmol/L), and 
outcome
Aneurysm location
ICA/MCA = 5/13
ACA/PComm = 3/3
Hanafy et al. (11)* 14 Prospective 
observational
Manuscript 48 years (range: 
34–59 years)
aSAH Primary: to measure CMD 
TNF-a post-aSAH
Admission WFNS:
IV in 1
V in 13
Secondary: to determine if 
clinical characteristics predict 
CMD TNF-a levels
Aneurysm locations:
ICA (4); MCA (3); ACA (6); VA (1)
Hanafy et al. (12)* 10 Retrospective 
case series
Manuscript 45.5 years 
(range: 
27–65 years)
aSAH Primary: to determine the 
correlation between CMD 
TNF-a and radiographic 
vasospasm as per CTA/DSA
Admission H + H:
2 in 1
3 in 1
4 in 3
5 in 5
Fisher CT: Secondary: none mentioned
Median = 3 (range: 2–4) 
Aneurysm locations: AComm (3); ICA 
(3); MCA (2); PCA (1); VA (1)
Helbok et al. (13) 26 Prospective 
observational
Manuscript 55 years (range: 
47–67 years)
aSAH Primary: to measure CMD 
IL-6 and CMD MMP-9 and 
determine the relationship to 
outcome
Admission H + H:
2 in 2
3 in 6
4 in 2
5 in 16
Secondary: to determine 
the temporal course of IL-6 
post-aSAH
Aneurysm location: unclear locations
Mellergård et al. (14) 21 with aSAH (38 
total in study with 
mixed pathology)
Prospective 
observational
Manuscript Unknown aSAH Primary: to evaluate CMD 
cytokine profiles immediately 
after insertion of the CMD 
catheter
No specifics on clinical status or 
aneurysms
Secondary: none mentioned
Mellergård et al. (15)* 88 with aSAH (Total 
145 patients with 
mixed pathology)
Retrospective 
case series
Manuscript Unknown aSAH Primary: to determine the 
CMD cytokine responds to 
aSAH
No specifics on clinical status or 
aneurysms
Secondary: none mentioned
Mellergård et al. (16)* 88 with aSAH (total 
145 patients with 
mixed pathology)
Retrospective 
case series
Manuscript Unknown aSAH Primary: to determine the 
CMD cytokine response to 
aSAH
No specifics on clinical status or 
aneurysms
Secondary: none mentioned
(Continued)
4
Zeiler et al. Systematic Review of Cytokines in SAH
Frontiers in Neurology | www.frontiersin.org August 2017 | Volume 8 | Article 379
Reference Number of 
patients
Study type Article 
location
Mean age 
(years)
Patient characteristics Primary and secondary 
goal of study
Sarrafzadeh et al. (17) 38 Prospective 
observational
Manuscript 53.1 years 
(range: unknown)
aSAH—29% with acute focal deficits 
on admission
Primary: to measure CMD, 
CSF and serum IL-6 
post-aSAHAdmission WFNS scores:
I in 12
II in 7
III in 3
IV in 7
V in 9
Mean Fisher CT score = 4 Secondary: correlate to 
clinical courseAneurysm locations: no specific given
Schiefecker et al. (18) 25 Prospective 
observational 
Manuscript Unknown aSAH—poor grade Primary: to evaluate CMD 
IL-6 levels post-aSAH and 
determine the association 
DIND and outcome at 
3 months
Secondary: determine 
probe relationship to IL-6 
expression
*Studies from the same Authors and Center – there may be duplicated patient information.
aSAH, aneurysmal subarachnoid hemorrhage; H + H, Hunt and Hess; WFNS, World Federation of Neurological Surgeons; CT, computed tomography; AComm, anterior 
communicating artery; PComm, posterior communicating artery; MCA, middle cerebral artery; ACA, anterior cerebral artery; ICA, internal cerebral artery; VA, vertebral artery; VBA, 
vertebrobasilar; PICA, posterior inferior cerebellar artery; CMD, cerebral microdialysis; CSF, cerebrospinal fluid; ICP, intracranial pressure; LPR, lactate:pyruvate ratio; IL, interleukin; 
MABP, mean arterial blood pressure; DC, decompressive craniectomy; DIND, delayed ischemic neurological deficit; PCA, principle component analysis.
TABLe 1 | Continued
TABLe 2 | CSF cytokine study characteristics and patient demographics.
Reference Number of 
patients
Study type Article 
location
Mean age 
(years)
Patient characteristics Primary and secondary goal of 
study
Chou et al. (19) 29 Prospective 
observational
Meeting 
abstract
Unknown aSAH Primary: to determine the association 
between CSF cytokines with 
vasospasm and patient outcome
Unknown admission clinical/radiologic 
grades
Secondary: none mentioned
No data on aneurysm characteristics
Graetz et al. (10) 24 Prospective 
observational
Manuscript 50 years (range: 
43.5–62 years)
aSAH Primary: to evaluate the pattern of IL-6 
expression in CMD, CSF, and serumAdmission WFNS:
I–III in 14
IV–V in 10
Mean Fisher Score: 4 (range: 3–4) Secondary: compare IL-6 expression 
to ICP, CMD-defined ischemia 
(LPR > 30, glycerol > 80 μmol/L), and 
outcome
Aneurysm Location:
ICA/MCA = 5/13
ACA/PComm = 3/3
Gruber et al. (20) 44 Prospective 
observational
Manuscript 51.3 years 
(range: 
24–80 years)
aSAH Primary: to measure CSF and serum 
cytokines. Determine any association 
to outcome.
Admission H + H:
I = 2
II = 4
III = 15
IV = 19
V = 4
Secondary: none mentioned
Aneurysm location:
Ant Circ = 30
Post Circ = 14
(Continued)
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Reference Number of 
patients
Study type Article 
location
Mean age 
(years)
Patient characteristics Primary and secondary goal of 
study
Höllig et al. (21) 46 (total 
81; only 46 
with CSF 
sampling)
Prospective 
observational
Manuscript 53.8 years 
(range: 
29–87 years)
aSAH Primary: to determine the relation 
of serum and CSF cytokines with 
discharge outcome.
Admission WFNS: Secondary: to determine the relation 
of serum and CSF cytokines with 
6-month outcome
Mean = 2.96
Admission Fisher Score:
Mean = 3.31
Aneurysm location:
AComm = 26
MCA = 17
ICA = 19
BA = 7
 “other” = 12
Mathiesen et al. (22) 22 Prospective 
observational
Manuscript 51.3 years 
(range: 
32–77 years)
aSAH Primary: to measure CSF cytokines in 
SAH patients and correlate to outcome 
and vasospasm.
Admission H + H:
I = 0
II = 14
III = 3
IV = 5
Secondary: none mentioned
Fisher CT score:
Not specified
Aneurysm location:
AComm = 9
MCA = 6
PComm = 3
ICA = 2
VA/VAB = 2
Nakahara et al. (23) 39 Prospective 
observational
Manuscript 62.9 years 
(range: 52–71)
aSAH Primary: to determine the correlation 
between HMGB-1 and other cytokines 
with patient outcome at 3 months
Admission H + H: Secondary: none mentioned
Range = 2–4
Fisher CT score:
Range = 3–4
Aneurysm location:
AComm = 12
MCA = 12
ICA/PComm = 11
ACA = 2
BA = 2
Niwa et al. (24) 10 Prospective 
observational
Manuscript 57 years (range: 
41–75 years)
aSAH Primary: to measure various CSF 
cytokines post-SAH. Determine 
association to patient outcome
Admission H + H:
I = 0
II = 6
III = 2
IV = 2
V = 0
Secondary: none mentioned
Fisher CT score:
I = 0
II = 0
III = 7
IV = 3
Aneurysm location:
AComm = 6
MCA = 2
ICA/PComm = 2
(Continued)
TABLe 2 | Continued
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(Continued)
Reference Number of 
patients
Study type Article 
location
Mean age 
(years)
Patient characteristics Primary and secondary goal of 
study
Provencio et al. (25) 14 Prospective 
observational
Meeting 
abstract
Unknown aSAH Primary: to determine the relationship 
between serum and CSF cytokines 
with patient outcome
Unknown admission clinical/radiologic 
grades
Secondary: none mentioned
No data on aneurysm characteristics
Sokół et al. (26) 10 Prospective 
observational
Manuscript 61.1 years 
(range: 
unknown)
aSAH Primary: to determine the association 
between CSF HMGB-1 and patient 
outcome
Admission H + H: Secondary: none mentioned
Mean = 4 (range: 4–4)
Admission Fisher CT score:
Mean = 4 (range: 2–4)
Aneurysm location:
AComm = 4
ACA = 2
BA = 2
PCA = 1
PICA = 1
Wada et al. (27) 45 Prospective 
observational
Meeting 
abstract
Unknown aSAH Primary: to determine the association 
between serum/CSF G-CSF and both 
vasospasm and patient outcome
Unknown admission clinical/radiologic 
grades
Secondary: none mentioned
No data on aneurysm characteristics
SHUNT DePeNDeNCY STUDieS
Douglas et al. (28) 20 Prospective 
observational
Manuscript 47 years (range: 
23–64 years)
aSAH Primary: to determine the association 
between CSF TGF-b1 and TGF-b2 
with shunt dependency post-aSAH
Admission WFNS:
I = 5
II = 4
III = 1
IV = 2
V = 6
ND = 2
Secondary: to compare CSF cytokines 
in aSAH and non-hemorrhage 
hydrocephalus patients
Admission Fisher CT score:
I = 1
II = 2
III = 3
IV = 11
ND = 3
Aneurysm location:
ACA = 3
ICA = 2
PCA = 1
PICA = 3
BA = 1
Traumatic = 1
ND = 8
Kitazawa and  
Tada (29)
24 Prospective 
observational
Manuscript 61.2 years 
(range: 
39–78 years)
aSAH Primary: to determine the association 
between CSF TGF-b1 levels and 
the development of CT-defined 
hydrocephalus and VPS dependency
unknown admission clinical grades
Admission Fisher CT grade:
II = 5
III = 14
IV = 3
Secondary: none mentioned
Aneurysm locations: unknown
TABLe 2 | Continued
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Reference Number of 
patients
Study type Article 
location
Mean age 
(years)
Patient characteristics Primary and secondary goal of 
study
Takizawa et al. (30) 36 Prospective 
observational
Manuscript 60.3 years 
(range: 
39–81 years)
aSAH Primary: to determine the association 
between CSF measured cytokines and 
the development of hydrocephalus
Unknown admission clinical/radiologic 
grades
Secondary: compare levels to  
non-hemorrhagic controls (n = 11)
No data on aneurysm characteristics
Wostrack et al. (31) 69 Prospective 
observational
Manuscript 57 years (range: 
21–80 years)
aSAH Primary: to determine the association 
between CSF cytokines and shunt 
dependency
Admission H + H:
I = 3
II = 17
III = 25
IV = 12
V = 12
Unclear Fisher grades Secondary: none mentioned
Aneurysm locations:
Anterior = 23
Middle = 16
ICA = 16
Posterior = 10
NiL ASSOCiATiON STUDieS
Gaetani et al. (32) 31 Prospective 
observational
Manuscript 52.6 years 
(range: 
unknown)
aSAH Primary: to determine the association 
between various CSF cytokines and 
the development of vasospasm
Admission WFNS:
1–2 = 24
3–4 = 7
Unclear Fisher grade and aneurysm 
Locations
Kaestner and  
Dimitriou (33)
27 (42 total; 
but non-
aneurysmal 
IVH in 15 
patients)
Prospective 
observational
Manuscript 52.2 years 
(range: 
unknown)
aSAH Primary: to determine the association 
between CSF TGF-b1 and 
hydrocephalus
Unknown admission clinical/radiologic 
grades
Secondary: to compare CSF TGF-b1 
with non-hemorrhagic communicating 
hydrocephalus (n = 7)Unknown aneurysm locations
Kim et al. (34) 51 (77 total; 
only 51 
with CSF 
samples)
Prospective 
observational
Manuscript Unclear mean 
and range
aSAH Primary: to determine the association 
between serum and CSF MIP-1 with 
patient outcome
Unknown admission clinical/radiologic 
grades
Secondary: to determine the 
association between serum and CSF 
MIP-1 with vasospasmNo data on aneurysm characteristics
Kwon and Jeon (35) 12 (19 
patients 
total; 12 with 
CSF)
Prospective 
observational
Manuscript 46.5 years 
(range: 
29–65 years)
aSAH Primary: to determine the relationship 
between serum/CSF cytokines and 
vasospasm. Also determine the link to 
patient outcome
Admission H + H:
I = 2
II = 6
III = 8
IV = 3
Secondary: none mentioned
Admission Fisher score:
I = 3
II = 5
III = 9
IV = 2
Aneurysm characteristics:
ACom = 8
MCA = 3
PCom = 5
ICA = 1
ACA = 1
VA = 1
TABLe 2 | Continued
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Reference Number of 
patients
Study type Article 
location
Mean age 
(years)
Patient characteristics Primary and secondary goal of 
study
Shoch et al. (36) 64 Prospective 
observational
Manuscript 55 years (range: 
29–77 years)
aSAH Primary: to determine the association 
between CSF IL-6 and vasospasm
Admission WFNS:
I = 9
II = 12
III = 4
IV = 25
V = 14
Secondary: none mentioned
Admission Fisher CT Score:
I = 0
II = 4
III = 32
IV = 28
Aneurysm Location:
ACA = 23
MCA = 12
AComm = 15
VBA = 14
Singh et al. (37) 13 Prospective 
RCT
Manuscript 54 years (range: 
40–69 years)
aSAH Primary: to evaluate the use of IV 
IL-1ra in aSAH and evaluated CSF 
cytokine response
Admission WFNS:
I = 1
II = 5
III = 0
IV = 3
V = 4
Secondary: to evaluate patient 
outcome
Admission Fisher CT score:
III = 3
IV = 10
Aneurysm location:
Anterior = 9
Posterior = 4
aSAH, aneurysmal subarachnoid hemorrhage; H + H, Hunt and Hess; WFNS, World Federation of Neurological Surgeons; RCT, randomized control trial; CT, computed tomography; 
VPS, ventriculoperitoneal shunt; IVH, intraventricular hemorrhage; AComm, anterior communicating artery; PComm, posterior communicating artery; MCA, middle cerebral artery; 
ACA, anterior cerebral artery; ICA, internal cerebral artery; VA, vertebral artery; VBA, vertebrobasilar; PICA, posterior inferior cerebellar artery; CMD, cerebral microdialysis; CSF, 
cerebrospinal fluid; ICP, intracranial pressure; LPR, lactate:pyruvate ratio; IL, interleukin; TGF, transforming growth factor; G-CSF, granulocyte colony-stimulating factor; HMGB, high-
mobility group box; MABP, mean arterial blood pressure; DC, decompressive craniectomy; PCA, principle component analysis.
TABLe 2 | Continued
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ReSULTS
Search Strategy Results
CMD Cytokine Search
Search strategy results for CMD cytokines in aneurysmal SAH 
can be seen within the flow diagram in Figure  1. At total of 
60 references were returned, all coming from the database 
search and none identified via meeting proceeding searches. 
After duplicate removal, there were 30 articles left for the 
assessment via the first filtering of title and abstract content. 
Thirteen articles passed the first filter, requiring acquisition 
of the full manuscript to assess inclusion eligibility. Through 
assessment of the full articles, nine manuscripts were deemed 
eligible for inclusion in the final CMD systematic review. No 
articles were added from the reference sections of either review 
papers or the parent manuscripts included in the systematic 
review.
CSF Cytokine Search
The search strategy flow diagram for the CSF cytokine scoping 
systematic review can be seen in Figure 2. Overall, 516 articles 
were identified, with 513 from the database search and 3 from 
published meeting proceedings. Two hundred and eighty dupli­
cates removed, leaving 236 references to review in the first filter. 
After implementation of the first filter, 61 articles were selected 
for assessment of their full manuscripts. One additional reference 
was added from the reference sections of review papers. After 
the second filter of full manuscripts, 20 articles were deemed eli­
gible for final inclusion in the CSF systematic review. Remaining 
articles were excluded due to non­relevance.
Patient/Study Demographics
CDM Cytokine Review
All of the nine articles included in the CMD cytokine portion 
of the systematic review all were formal manuscript publications 
TABLe 3 | CMD cytokine measures and outcomes.
Reference Catheter location 
and measured 
CMD cytokines
interventional 
therapies 
applied during 
measurement
Primary outcome Secondary outcome Complications 
to CMD
Conclusions
Graetz et al. (10) Inserted into 
territory of aneurysm 
(whether healthy or 
injured)
Protocolized 
therapy for 
monitoring and Tx 
of ICP; 3 patients 
underwent DC
IL-6 in CSF and CMD 
were typically higher 
than in serum
ICP: CMD and CSF IL-6 levels 
were higher in the high ICP 
patients, with significant for 
CMD samples (p = 0.029)
Not specified 1. IL-6 levels in CSF, 
CMD, and serum 
are elevated after 
aSAH
2. CMD IL-6 levels are 
higher in those with 
ICP issues
3. No correlation 
between CMD IL-6 
and ischemia
4. Potential weak 
association 
between CMD IL-6 
levels and outcome 
at 3 and 6 months
IL-6 CMD IL-6 levels increased after 
day 4 in the high ICP group
Unclear pooled 
analysis over a 
10 days period
Ischemia (as per LPR > 30 
and glycerol > 80 μmol/L): no 
correlation between CMD, CSF, 
or serum IL-6 and ischemia
Ringer’s perfusate 
utilized
20 patients 
clipped
Outcome (dichotomized GOS at 
3 and 6 months): high CMD IL-6 
levels were associated with poor 
outcome (p = 0.06)
Hanafy et al. (11)* Unclear tissue 
location
Unclear DIND 
monitoring; 
various ICP/CPP 
directed therapies
TNF-a as measured via 
CMD is feasible and 
elevated post-SAH
Only the existence of IVH and 
aneurysm size >6 mm was 
correlated to TNF-a levels in 
CMD
Not specified TNF-a is elevated in 
CMD post-aSAH
TNF-a
q6 hour sampling for 
unclear duration
Unclear Surgical 
Tx
IVH and large 
aneurysm size is 
associated with 
elevated CMD TNF-a 
levels
Isotonic crystalloid 
perfusate
Hanafy et al. (12)* Unclear tissue 
location
Not specified; 
unclear surgical Tx
Increase CMD TNF-a 
between days 4 and 6 
post-hemorrhage was 
associated with a worse 
radiographic vasospasm 
index (p < 0.01)
N/A Not specified Elevated CMD TNF-a 
levels may correlation 
with radiographic 
vasospasm
TNF-a
q6 hour sampling for 
unclear duration
No comments 
were made on the 
relationship to DIND 
secondary to cerebral 
vasospasm
Isotonic crystalloid 
perfusate
Helbok et al. (13) “Right frontal” in 
mixed tissue states
Protocolized 
investigations 
for vasospasm, 
otherwise unclear 
ICU treatments
3-month mRS No correlation between IL-6 and 
MMP-9 via CMD
Not specified CMD IL-6 may be 
associated with 
outcome at 3 monthsIL-6
Unclear sampling 
interval
18 patients 
clipped; some 
had DC
CMD IL-6 and LPR 
were higher in those 
patients with worse 
mRS at 3 months 
(p = 0.01)
IL-6 was highest initially after 
bleed and in cases where 
rebleed occurredIsotonic crystalloid 
perfusate
Mellergård  
et al. (14)
Mixed locations; 
some patients with 
2 catheters (unclear 
which patients)
Not specified IL-1b peaked in the first 
12 h period
N/A Not specified CMD catheter insertion 
leads to IL-1b/IL-6/
IL-8/MIP-1b within 
the first 6–12 h, which 
then decrease during 
the subsequent time 
afterward
IL-1b, IL-6, IL-8, 
FGF-2, MIP-1β, 
RANTES, VEGF, 
IL-10
IL-6 peaked after 12 h 
post-insertion
q6 hour pooled 
samples for 36 h
IL-8 peaked within the 
first 6 h post-insertion
Ringer-Dextran 60 
perfusate
MIP-1b peaked 
within the first 6 h 
post-insertion
(Continued)
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Reference Catheter location 
and measured 
CMD cytokines
interventional 
therapies 
applied during 
measurement
Primary outcome Secondary outcome Complications 
to CMD
Conclusions
FGF-2 peaked 
within the first 6 h 
post-insertion
IL-10, VEGF, and 
RANTES did not show a 
temporal profile
Mellergård  
et al. (15)*
Some with paired 
catheters (1 peri-
lesonal; 1 healthy 
tissue)—used the 
catheter with  
highest glycerol 
levels for measuring 
cytokines
Not Specified IL-1b increased during 
the first 48 h and then 
decreased
N/A Not specified IL-1b and IL-6 display 
a peak elevation 
during the first 48 h 
post-aSAH
IL-1b, IL-6, IL-10 IL-6 increased over 
the first 48 h and then 
decreased
q6 hour pooled 
analysis for 7 days
65 patients 
clipped
IL-10 remained 
elevated throughout the 
measurement period
IL-10 remains elevated 
through the first 7 days 
post-aSAH
Ringer-Dextran 60 
perfusate
No comments on 
cytokine profiles in 
clipping vs. coiling 
patients were made
Mellergård  
et al. (16)*
Paired catheters 
(1 perilesonal; 1 
healthy tissue)—
used the catheter 
with highest glycerol 
levels for measuring  
cytokines
Not specified FGF-2 levels peaked at 
day 3 post-TBI
N/A Not specified FGF-2/VEGF levels 
peaked on days 3 and 
2 post-aSAH
FGF-2, VEGF
q6 hour pooled 
analysis for 7 days
65 patients 
clipped
VEGF levels peaked 
on day 2 post-aSAH 
and were higher in 
those whom underwent 
surgical clipping
Surgical clipping 
changes the 
inflammatory mediator 
expression in CMD
Ringer-Dextran 60 
perfusate
Sarrafzadeh  
et al. (17)
Single catheter 
in territory where 
aneurysm located
Not specified IL-6 levels in CMD and 
CSF were higher than 
serum
N/A Not specified IL-6 levels are elevated 
in CMD and CSF 
post-aSAH
IL-6 Unclear surgical 
Tx for aneurysm
IL-6 levels in CSF, 
CMD, and serum 
were higher in those 
with symptomatic 
vasospasm but was not 
predictive
2–3 times daily for 
10 days
Some received DC However, CMD and 
CSF IL-6 levels 
were higher in 
those presenting 
with acute deficits 
and predicted the 
development of further 
DIND secondary to 
vasospasm on day 7 
post-bleed (p = 0.025)
IL-6 CMD levels 
may be predictive of 
DIND secondary to 
vasospasm in those 
presenting with acute 
deficits
Ringer’s perfusate 10 developed 
DIND secondary 
to vasospasm—Tx 
unclear
TABLe 3 | Continued
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Reference Catheter location 
and measured 
CMD cytokines
interventional 
therapies 
applied during 
measurement
Primary outcome Secondary outcome Complications 
to CMD
Conclusions
Schiefecker  
et al. (18)
Mixed locations Not specified Patients were 
categorized into low-
grade or high-grade 
inflammation based on 
median CMD IL-6 levels
CMD probe location: peri-
lesional location associated with 
high IL-6 levels (p = 0.002)
Not specified CMD IL-6 levels are 
higher in peri-lesional 
areas and in patients 
with ICH post-aSAH
IL-6 Brain extracellular 
TAU-protein levels 
(p = 0.001), metabolic 
distress, and delayed 
cerebral infarction 
(p = 0.001) were 
linked to high-grade 
neuroinflammation
Unclear sampling 
interval
Outcome: high-grade 
neuroinflammation 
was a predictor for 
worse outcome three 
months after ictus, 
independently from 
probe location, initial 
H + H grade and age 
(p = 0.01)
ICH: presence of ICH was 
associated with elevated IL-6 
levels (p = 0.003)
CMD IL-6 levels may 
be associated with 
DIND and outcome at 
3 months
Unknown perfusate
*Studies from the same Authors and Center – there may be duplicated patient information.
aSAH, aneurysmal subarachnoid hemorrhage; ICH, intracerebral hemorrhage; IVH, intraventricular hemorrhage; mRS, modified Rankin scale; GOS, Glasgow outcome scale; H + H, 
Hunt and Hess; CMD, cerebral microdialysis; LP, lumbar puncture; ICP, intracranial pressure; CSF, cerebrospinal fluid; LPR, lactate:pyruvate ratio; DC, decompressive craniectomy; 
IL, interleukin; a, alpha; b, beta; g, gamma; TNF, tumor necrosis factor; INF, interferon; MIP, macrophage inflammatory proteins; TNFR, tumor necrosis factor receptor; VEGF, 
vascular endothelial growth factor; FGF, fibroblast growth factor; DIND, delayed ischemic neurological deficit; TBI, traumatic brain injury; ICU, intensive care unit.
TABLe 3 | Continued
TABLe 4 | CSF cytokine measures and outcomes.
Reference interval of 
cytokine 
measure
CSF 
cytokines 
measured
interventional 
therapies 
applied during 
measurement
Outcome of interest Other interesting 
CSF cytokine-related 
outcomes
Conclusions
PATieNT FUNCTiONAL OUTCOMe
Chou et al. (19) EVD-based 
sampling
IL-2, IL-4, 
IL-5, IL-6, 
EGF, 
fractalkine, 
PDGF-AA
Not specified Outcome assessed via mRS at 6 months: N/A CSF IL-4 may be 
associated with 6 
month outcomeUnclear 
sampling interval
Unclear clip vs. 
coil numbers
IL-4 (0 = 0.02) associated with good 
6-month mRS
No association between CSF cytokines and 
vasospasm
Graetz et al. (10) EVD-based 
sampling
IL-6 Protocolized 
therapies 
directed toward 
ICP/CPP and 
vasospasm 
monitoring via 
TCD
Outcome assessed via dichotomized 
GOS at 3 and 6 Months (good = 4 or 5; 
poor = 1–3)
Vasospasm: CSF IL-6 may be 
associated with 
outcome at 6 months
Q8 hours for 
days 0–4
Unclear clip vs. 
coil numbers
CSF IL-6 on days 5–9 post-bleed were 
associated with 6 month outcome 
(p < 0.05)
No correlation between 
CSF IL-6 and DIND
Q12 hours for 
days 5–10
Micodialysis based 
Ischemia (LPR > 30, 
glutamate > 80 μmol/L):
No association between 
CSF IL-6 and CMD-
based ischemia
(Continued)
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Reference interval of 
cytokine 
measure
CSF 
cytokines 
measured
interventional 
therapies 
applied during 
measurement
Outcome of interest Other interesting 
CSF cytokine-related 
outcomes
Conclusions
Gruber et al. (20) EVD-based 
sampling
sTNFR-I, 
IL-1ra, 
TNF-a, 
TNF-b, 
IL-1a, IL-1b
15 patients 
clipped
Outcome assessed via GOS at 6 months: Vasospasm: CSF IL-1ra, sTNFR, 
IL-6 may be associated 
with poor outcome at 
6 months
Day 1, 3–5, 6–8, 
9–11 post-bleed
Otherwise not 
specified
Elevated CSF IL-1ra (p < 0.001), sTNFR 
(p = 0.02), and IL-6 (p = 0.001) were 
associated with outcome
IL-1ra correlated to 
DIND (p = 0.04)
IL-1ra peaked ~day 6 
post-bleed and then 
decreased in good 
grade patients, while 
it remained elevated in 
poor grade patients
Höllig et al. (21) EVD-based 
sampling
IL-6, LIF, 
E-selectin, 
ICAM-1
Not specified Outcome assessed via dichotomized mRS 
(good = 0–2; poor = 3–6)
N/A CSF LIF at day 1 
post-admission may 
be associated with 
outcome a discharge
At day 1 only 18 patients 
clipped
Outcome at Discharge:
CSF LIF was associated with discharge 
outcome
Outcome at 6 months:
None of the measured cytokines were 
associated with outcome
Mathiesen  
et al. (22)
EVD-based 
sampling 
(control group 
had banked LP 
CSF)
IL-1a, 
IL-1b, 
IL-1ra, 
TNF-a
Not specified Outcome assessed via dichotomized GOS 
at unspecified interval (good = 4 or 5; 
poor = 1–3)
Vasospasm: CSF IL-1ra and TNF-a 
measured at day 
~3–11 post-bleed may 
be associated with 
outcome
Unclear 
sampling 
intervals
Unclear clip vs. 
coil numbers
Elevated CSF IL-1ra (p < 0.05) and TNF-a 
(p < 0.05) at days 3–11 were associated 
with poor outcome
CSF IL-1ra was elevated 
in all patient with DIND 
(n = 3)
Controls:
All CSF cytokines were 
elevated compared to 
control samples
Nakahara  
et al. (23)
EVD-based 
sampling
HMGB-1, 
IL-6, IL-8, 
TNF-a
Not specified Outcome assessed via dichotomized GOS 
at 3 months (good = 4 or 5; poor = 1–3)
N/A CSF HMGB-1, IL-6, 
IL-8, and TNF-a may 
be associated with 
outcome at 3 months
Day 3, 7, and 14 
post-admission
All underwent 
clipping
CSF HMGB-1, IL-6, IL-8, and TNF-a were 
elevated in the poor outcome group
Niwa et al. (24) EVD-based 
sampling
IL-6, MCP-
1, IL-10, 
MIG
Not specified Outcome assessed via dichotomized GOS 
at 3 months (good = 4 or 5; poor = 1–3)
N/A CSF IL-6 may be 
associated with 
outcome at 3 monthsDaily for 14 days All underwent 
clipping
Peak IL-6 was associated with poor 
outcome
Provencio  
et al. (25)
EVD-based 
sampling
IL-1a, 
IL-1ra, IL-2, 
IL-8, IL-17, 
TNF-a, 
INF-g
Not specified Outcome assessed via dichotomized 
mRS at unspecified interval (good = 1–2; 
poor = 3–5)
N/A CSF IL-1a, IL-1ra, 
IL-2, IL-8, IL-17, 
TNF-a, and INF-g may 
be associated with 
outcome at 3 months
Daily for first 
3 days
Unclear clip vs. 
coil numbers
Elevated CSF levels of IL-1a, IL-1ra, IL-2, 
IL-8, IL-17, TNF-a, and INF-g were found in 
the poor outcome group (all p < 0.05)
Sokół et al. (26) EVD-based 
sampling 
(control group—
non-ill patients 
with banked LP 
CSF)
HMGB-1 Not specified Outcome assessed via dichotomized GOS 
at 3 months (good = 4 or 5; poor = 1–3)
Controls: CSF HMGB-1 may be 
associated with poor 
outcome
Day 1, 5, and 
10 post-bleed
All coiled CSF HMGB-1 levels were elevated at all 
3 time points in those with poor outcome. 
Levels above 10 ng/mL were found in all 
with poor outcomes
SAH patients had 
higher HMGB-1 levels 
compared to controls
TABLe 4 | Continued
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Reference interval of 
cytokine 
measure
CSF 
cytokines 
measured
interventional 
therapies 
applied during 
measurement
Outcome of interest Other interesting 
CSF cytokine-related 
outcomes
Conclusions
Wada et al. (27) LD-based 
sampling
G-CSF Not specified Outcome assessed via mortality at 
unspecified interval
Vasospasm: CSF G-CSF levels may 
be associated with 
mortalityDay 1, 3, 
6, and 9 
post-admission
8 clipped Day 1 elevated G-CSF levels were 
associated with mortality
No correlation between 
CSF G-CSF levels and 
vasospasm
SHUNT DePeNDeNCY STUDieS
Douglas et al. (28) EVD-based 
sampling
TGF-b1, 
TGF-b2
Not specified Hydrocephalus as measured via F/U CT at 
2 months:
Controls comparison: CSF TGF levels within 
the acute phase post-
aSAH may predict 
chronic communicating 
hydrocephalus
Q2 day sample 
intervals (control 
samples 
collected from 
7 patients 
with non-
hemorrhagic 
communicating 
hydrocephalus)
Unclear clipping 
vs. coiling 
numbers
CSF total TGF levels were higher in those 
patients whom developed CT-based 
hydrocephalus (p < 0.05)
CSF TGF levels were 
higher in aSAH patients 
vs. controls
Kitazawa and 
Tada (29)
Cisternal CSF or 
LD sampling
TGF-b1 Not specified Shunt dependency at 3 months: N/A CSF TGF-b1 levels 
during the second 
week post-aSAH may 
be associated with 
the development of 
ventriculomegaly and 
VPS dependency
Unclear 
sampling interval 
up to day 17
23 clipped No relation between CSF TGF-b1 and CT 
based peri-ventricular Hounsfield units
CSF TGF-b1 on days 9–17 were higher 
in those whom developed ventricular 
dilatation on CT (p < 0.02) and VPS 
dependency (p < 0.02)
Takizawa et al. (30) LP at day 14 
post-bleed
IL-1b, IL-6, 
TGF-b1
Not specified Shunt dependency at unspecified interval: Control comparison: CSF TGF-b1 levels at 
2 weeks post-bleed 
may be associated with 
shunt dependency
Control samples 
collected via LP
Unclear coil vs. 
clip numbers
TGF-b1 levels were higher in those 
requiring a VPS
CSF levels of all 
cytokines were higher in 
the aSAH group
Wostrack et al. (31) EVD-based 
sampling
IL-6 Not specified Shunt dependency at unspecified interval: N/A CSF IL-6 levels may be 
associated with VPS 
dependencyQ2 days for 
14 days
Unclear coil vs. 
clip numbers
CSF IL-6 > 10,000 pg/mL was associated 
with VPS dependency (p = 0.009)
NiL ASSOCiATiON STUDieS
Gaetani et al. (32) Cisternal CSF 
gathered at 
surgery
IL-6, IL-8, 
MCP-1, 
E-selectin
Not specified Vasospasm: N/A CSF IL-6, IL-8, 
MCP-1, E-selectin are 
not associated with 
vasospasm
All were clipped No association between measured CSF 
cytokines and development of vasospasm 
(TCD MCA > 160 cm/s)
Kaestner and 
Dimitriou (33)
EVD-based 
sampling
TGF-b1, 
TGF-b2
Not specified Chronic hydrocephalus (defined on CT 
and need for VPS; followed for 6 months 
post-bleed):
N/A CSF TGF-b1 and 
TGF-b2 levels are not 
associated with post-
aSAH hydrocephalus 
or VPS dependency
Daily for 10 days Unclear coil vs. 
clip numbers
No correlation between CSF TGF levels 
with hydrocephalus and VPS dependency
Kim et al. (34) EVD or LD 
sampling
MIP-1 Not specified Outcome assessed via dichotomized mRS 
(good = 0–3; poor = 4–6) at discharge:
Vasospasm: CSF MIP-1 does not 
predict discharge 
outcome or vasospasmDaily up to day 
14
Unclear clip vs. 
coil numbers
CSF MIP-1 was not predictive of outcome CSF MIP-1 provides 
unclear prediction of 
vasospasm post-aSAH
Kwon and  
Jeon (35)
EVD-based 
sampling
IL-1b, IL-6, 
TNF-a
“Triple H 
therapy”; not 
otherwise 
specified
Outcome assessed via dichotomized GOS 
at unspecified interval (good = 4 or 5; 
poor = 1–3)
Vasospasm: CSF IL-1b, IL-6, and 
TBF-a do not correlate 
with outcome at 
6 months
Unclear intervals Unclear clip vs. 
coil numbers
None of the measured cytokines were 
associated with outcome
CSF IL-6 levels were 
higher in the DIND group 
(p < 0.05)
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Reference interval of 
cytokine 
measure
CSF 
cytokines 
measured
interventional 
therapies 
applied during 
measurement
Outcome of interest Other interesting 
CSF cytokine-related 
outcomes
Conclusions
Shoch et al. (36) EVD-based 
sampling
IL-6 Not specified Vasospasm (as assessed via TCD): N/A CSF IL-6 is not 
associated with patient 
outcome
Daily for 14 days 65% treated via 
coiling
Elevated peak CSF IL-6 on day 6 post-
bleed was associated with TCD-defined 
vasospasm
CSF IL-6 may predict 
TCD vasospasm and 
subsequent DIND
DIND was associated with day 7 CSF IL-6 
(p = 0.03)
Outcome as assessed by dichotomized 
mRS at unspecified interval (good = 0–2; 
poor = 3–6)
No association between IL-6 and patient 
outcome
Singh et al. (37) EVD-based 
sampling
IL-1ra, 
IL-1a, 
IL-1b, IL-6, 
IL-8, IL-10, 
MCP-1, 
TNF-a
Randomized 
to standard 
therapy (n = 7) 
or IV IL-1ra 
(n = 6)
Outcome as assessed by GOS at 6 
months:
IV IL-1ra lead to a 
decrease in CSF IL-6 
from 6 to 24 h post-
bleed, compared to 
placebo group
CSF cytokines are not 
associated with patient 
outcome (note: studied 
underpowered = 
acknowledged in 
manuscript)Q6 hours for 
24 h post 
infusion of IL-1ra
Unclear clip vs. 
coil numbers
No association between CSF cytokine 
factors and outcome (i.e., Decreased 
CSF cytokine levels with IL-1ra were not 
associated with outcome)
aSAH, aneurysmal subarachnoid hemorrhage; mRS, modified Rankin scale; GOS, Glasgow outcome scale; CMD, cerebral microdialysis; EVD, external ventricular drain; LP, 
lumbar puncture; VPS, ventriculoperitoneal shunt; ICP, intracranial pressure; CT, computed tomography; CSF, cerebrospinal fluid; LPR, lactate:pyruvate ratio; DC, decompressive 
craniectomy; IL, interleukin; a, alpha; b, beta; g, gamma; TNF, tumor necrosis factor; INF, interferon; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory 
proteins; TGF, transforming growth factor; EGF, epidermal growth factor; TNFR, tumor necrosis factor receptor; GM-CSF, granulocyte macrophage colony-stimulating factor; HMGB, 
high-mobility group box; DIND, delayed ischemic neurological deficit; CPP, cerebral perfusion pressure; TCD, transcranial Doppler; sTNFR, soluble tumor necrosis factor receptor; 
PDGF, platelet-derived growth factor; MCA, middle cerebral artery.
TABLe 4 | Continued
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(10–18). There were six prospective studies, with all being pro­
spective observational studies (10, 11, 13–15, 18). Three studies 
were retrospective case series (12, 16, 17).
A total of 246 unique patients with SAH were described across 
the 9 studies included in the CMD cytokine review. Two studies 
reported the same group of 88 SAH CMD patients, with a focus 
on analyzing different cytokine measures (15, 16). We took this 
into account during the calculation of the total patient numbers, 
to avoid counting patients twice.
The patient populations described within the CMD cytokine 
manuscripts were heterogeneous collections of aneurysmal SAH. 
The majority of studies focused on patients with poor admission 
clinical grades, classified as Hunt and Hess (H + H) grade 3–5, 
or as World Federation of Neurological Surgeons (WFNS) grade 
3–5; often with high Fisher CT grade hemorrhages (i.e., 3 or 4). 
Aneurysm locations varied between studies, with some included 
both anterior and posterior circulation aneurysms. When 
recorded, the highest percentage of aneurysms was located within 
the anterior circulation with: anterior communicating artery 
(AComm), middle cerebral artery (MCA), and posterior com­
municating artery (PComm) locations predominating. Three 
studies failed to disclose patient clinical grade, radiographic 
grade, and aneurysm location information (14–16). Therapies 
received in the ICU were not clearly specified in the majority 
of the studies. Similarly, aneurysm treatment technique varied 
between and within the individual studies, with microsurgical 
clipping predominating.
We believe that some of the studies included within this por­
tion of the review may contain duplicate patient information, as 
marked in Tables 1 and 3. Multiple publications from the same 
research groups likely were conducted on the same patient popu­
lations, yielding unique and separate manuscripts on the same 
group of patients. However, it is important to acknowledge that it 
was difficult to determine, in some circumstances, whether CMD 
cytokine analysis was being conducted on new patient groups or 
existing banked samples from previous prospective studies. With 
that said, our goal for the CMD cytokine scoping review was to 
provide an overview of all available literature in the area; hence, 
we have included all published papers on CMD cytokines in 
aneurysmal SAH within this review.
CSF Cytokine Review
Of the 20 articles included in the CSF cytokine systematic 
review (10, 19–37), 17 were formal manuscript publications 
(10, 20–24, 26, 28–37) and 3 were meeting abstract publica­
tions (19, 25, 27). All were prospective studies, with 19 being 
observational studies (10, 19–36) and 1 being a randomized 
control trial (37).
The populations described with in the CSF cytokine studies 
were quite heterogeneous, similar to the CMD cytokine papers. 
Most studies focused on patients with poor clinical grade (i.e., 
H + H 3–5; WFNS 3–5), and high Fisher CT grade (i.e., 3 or 4) 
upon admission. Aneurysm location varied significantly between 
papers with both anterior and posterior circulation aneurysms 
FiGURe 1 | Flow diagram of search results for cerebral microdialysate cytokines.
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included in the studies. The majority of patients had anterior 
circulation aneurysms with AComm, MCA, and PComm rep­
resenting the three most common locations. Therapies received 
within the ICU were either not specified or minimally character­
ized, leading to potentially significant treatment heterogeneity 
during CSF cytokine measurement. Finally, aneurysm treatment 
technique was unspecified in many studies (10, 19, 22, 25, 28, 30, 
31, 33–35, 37). Those studies which disclosed aneurysm treat­
ment employed both coiling and microsurgical clipping (20, 21, 
23, 24, 26, 27, 29, 32, 36).
A total of 630 patients were described across all studies 
included in the CSF cytokine systematic review. The mean age 
for each study cohort varied significantly across studies, with all 
studies focusing on adult aneurysmal SAH. Details surrounding 
patient cohort, study design, and concurrent therapies can be 
found in Tables 2 and 4.
We made substantial efforts to exclude duplicate patient data 
across studies. However, given that many of the papers came from 
centers of excellence for TBI research, some of the patient data 
may be cross reported in multiple studies. This would reduce the 
total overall number of unique patients slightly. It was impossible 
based on the information provided within the parent studies to 
tease out all patients, which were reported more than once.
Cytokine Measurement Technique
CMD Cytokine Review
Location of the CMD catheter varied significantly between stud­
ies and was the following: mixed healthy/peri­lesional tissue in 
six studies (13–16, 18), territory of the aneurysm in two studies 
(10, 17), and unknown tissue location in two studies (11, 13). 
Some studies utilized paired microdialysis catheters, one in 
healthy and one in peri­lesional tissue (15, 16).
Analysis interval for CMD samples was as follows: every 6 h in 
five studies (11, 12, 14–16), every 8–12 h in one study (17), and 
unspecified in three studies (10, 13, 18). The duration of sample 
collection varied as well, with the typical collection period of 36 h 
to 10 days.
Numerous different panels of cytokines were evaluated within 
the CMD samples, across the studies included within the review. 
The most commonly studied cytokines included IL­1b, IL­6, 
FiGURe 2 | Flow diagram of search results for cerebrospinal fluid cytokines.
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IL­10, and TNF­a. Details surrounding CMD technique and 
catheter locations can be seen in Table 3.
CSF Cytokine Review
Sampling of CSF was conducted through external ventricular 
drains (10, 19–26, 28, 35–37), cisternal collection intraoperatively 
(29, 32), or by lumbar puncture (27, 29, 30, 34). Sampling and 
analysis frequency varied significantly from study to study with 
sampling occurring from daily to every 2–3  days. Duration 
of sampling varied as well, up to a maximum of 14 days post­ 
ictus (31).
Like the CMD cytokine papers, the CSF cytokine papers 
included in this review reported the measurement of various 
cytokines. The most commonly measured cytokines in CSF 
reported were IL­1b, IL­1ra, IL­6, IL­8, TNF, TGF, and MIP. The 
details of CSF sampling and specific cytokines measured can be 
found in Table 4.
Outcomes
CMD Cytokine Review
Given that the CMD cytokine portion of this review was a scop­
ing review, providing an overview of all the available literature 
on CMD cytokine measures in aneurysmal SAH, the outcomes 
reported by the studies are quite heterogenous. They can be seen 
in detail in Table 3.
Three studies reported the correlation between CMD 
cytokines and patient outcome (10, 13, 18). All of these three 
studies reported a correlation between elevated CMD IL­6 levels 
and poor outcome at 6  months, measured using the Glasgow 
Outcome Scale (GOS) (10), 3 months measured using the modi­
fied Rankin scale (mRS) (p =  0.01) (13), or other unspecified 
outcome scales (p < 0.01) (18).
Both the presence of intraventricular hemorrhage and intrac­
erebral hemorrhage (ICH) post­aneurysm rupture were associ­
ated with elevated CMD IL­6 (p = 0.003) (18) and TNF­a (11). 
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Similarly, peri­lesional probe CMD probe location was associated 
with higher IL­6 levels compared to more distant probe locations 
(p = 0.002) (18).
Radiographic cerebral vasospasm was found to be associated 
with elevated CMD TNF­a on day 4 and 6 post­ictus in one study 
(p <  0.01) (12). Similarly, elevated total CMD IL­6 levels were 
found to be associated with radiographic vasospasm in one study 
(17). However, there was an unclear association with the develop­
ment of DIND.
Many studies provided descriptions of CMD cytokine profiles 
and temporal patterns. Given the various cytokines measured 
across the studies, it is impossible to describe all of these relation­
ships, but highlights from these analyses are presented in Table 3. 
Broadly speaking, the data show temporal variations in cytokine 
levels, with peaks in IL­1b, IL­6, IL­8, and MIP between 6 and 
12 h post­bleed (14, 15). On the other hand, IL­10 levels in CMD 
remained constantly elevated throughout the analysis periods 
recorded (14, 15).
CSF Cytokine Review
Within the 20 papers included in the CSF systematic review 
(10, 19–37), we found both manuscripts which reported posi­
tive associations between CSF cytokines with patient outcome/
chronic hydrocephalus/VPS dependency (10, 19–31) and studies 
reporting no association (32–37) (i.e., “nil association”) between 
CSF cytokines and the outcomes of interest for the CSF cytokine 
systematic review. No studies identified reported association, 
“nil” or otherwise, between CSF cytokine measures and tissue 
outcome as assessed by follow­up neuroimaging. The subsections 
below describe more details around these outcomes of interest, 
with further information found in Table 4.
Positive Association Studies
Fourteen papers included within the CSF cytokine review found 
associations between measured cytokines with both patient 
outcome and/or chronic hydrocephalus/VPS dependency. Ten 
of these reported an association between CSF cytokines and 
patient outcome (10, 19–27). Four papers reported an association 
between CSF cytokine measures and the development of chronic 
hydrocephalus/VPS dependency (28–31).
Patient Outcome. The strongest relationships between CSF 
cytokine levels and clinical outcome (defined using the GOS 
or mRS) were seen for IL­6 (10, 20, 23, 24), IL­1ra (20, 22, 25), 
IL­8 (23, 25), and TNF­a/sTNFR (20, 22, 23, 25). Associations 
between CSF levels of high­mobility group box­1 (26), G­CSF 
(27), LIF (21), and IL­1a (25) and poor patient outcome were 
also described.
Chronic Hydrocephalus/VPS Dependency. Four studies dis­
cussed the correlation between CSF cytokines and the devel­
opment of chronic hydrocephalus/VPS dependency (28–31). 
One study showed that CSF TGF­b1 and TGF­b2 levels were 
associated with the development of hydrocephalus (defined 
using CT imaging) at 2 months post­bleed (p < 0.05) (28). A 
second study also documented the correlation between elevated 
CSF TGF­b1 during the patients ICU stay and the development 
of radiographic hydrocephalus or VPS dependency at 3 months 
(p < 0.02) (29). A third study confirmed that CSF TGF­b1 lev­
els were elevated during the acute/subacute phase in those who 
became shunt dependent (30). Finally, one study documented 
that CSF IL­6 levels during the acute/subacute phase post­bleed 
to be associated with VPS dependency at an unclear interval 
(p = 0.009) (31).
Nil Association Studies
Our review identified six studies documenting a “nil association” 
between CSF measured cytokines in aneurysmal SAH patients 
and various outcomes of interest (32–37).
Four studies reported no association between various CSF 
cytokines and patient outcome, as reported by in­hospital mortal­
ity or GOS at 3–6 months (34–37). The cytokines reported within 
these studies varied significantly, with the most common “nil 
associations” reported for MIP (34), IL­1b (35, 37), IL­6 (35, 37), 
and TNF­a (35, 37). A total of 140 patients were described within 
these studies, compared to the 283 patients within the studies 
documenting a correlation between CSF measured cytokines and 
patient outcome (10, 18–27).
Two studies reported no association between CSF cytokine 
measures and TCD­based flow velocity (32, 36), while one study 
failed to show an association between CSF TGF and VPS depend­
ency (33). Further detail on the “nil association” studies can be 
found at the bottom of Table 4.
Complications
Within the CMD cytokine manuscripts, all manuscripts failed to 
report whether complications were considered within the data 
collection. We suspect that complication profiles are dramatically 
underreported within the CMD studies.
Complication reporting within the CSF cytokine studies was 
essentially non­existent, with the focus of these studies being 
the association between CSF cytokine measures and various 
outcomes.
DiSCUSSiON
CMD Cytokines in SAH
The scoping systematic review on CMD cytokines in aneurysmal 
SAH yielded nine studies. Despite the small number of studies 
and patients described within, there are a few points of interest 
that deserve highlighting. First, CMD­based measurement of 
cytokines is feasible in this patient population. Second, CMD 
catheter location makes a difference in the levels of cytokines 
measured, with peri­lesional tissue producing high levels com­
pared to distant or healthier tissue (18). Third, peaks in CMD 
cytokine measures may occur within the first 6–12 h for IL­1b, 
IL­6, IL­8 and, MIP, while IL­10 seems to remain elevated in CMD 
samples through the duration of the sampling periods described 
(14, 15). Fourth, CMD IL­6 levels may be associated with poor 
outcome (10, 13, 18), up to 6 months post­injury. Finally, com­
plications related to the use of CMD catheters are underreported, 
and there is a concern of selective harms reporting within the 
literature identified.
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CSF Cytokines in SAH
The systematic review on CSF cytokines in aneurysmal SAH, 
focused on the association between cytokine measures with 
patient outcome, chronic hydrocephalus/VSP dependency, 
neurophysiologic outcome, or tissue outcome. We identified 
some interesting trends from the 20 included studies (10, 19–37). 
First, a broad range of cytokines or panels of cytokines were 
described in these studies, but the strongest associations with 
poor outcome were found for elevated CSF levels of: IL­6 (10, 
20, 23, 24), IL­1ra (20, 22, 25), IL­8 (23, 25), and TNF­a/sTNFR 
(20, 22, 23, 25). Second, acute/subacute CSF levels of TGF­b1 and 
TGF­b2 seemed to be associated with chronic hydrocephalus or 
shunt dependency at 2–3 months post­bleed (28–30). Third, we 
were unable to identify any studies documenting an association 
between CSF cytokines measures in SAH with neurophysiologic 
or tissue­based outcomes. Fourth, despite the “positive” associa­
tions found in the previously described papers, four manuscripts 
found no relationship between CSF cytokines and patient outcome 
(34–37). The patient numbers within these studies were smaller 
than that in the studies describing a positive association between 
CSF cytokines and patient outcome, with the “nil association” 
studies totaling 140 patients and the “positive association” studies 
totaling 286 patients. Finally, the complication reporting within 
the CSF cytokine studies was absent. Selective reporting bias here 
is a major concern.
Limitations
Despite the interesting results of these two systematic reviews, 
there are significant study limitations that need to be highlighted. 
Limitations with each separate review can be found within the 
subsections to follow. Two limitations affected both reviews.
First, which was eluded to within the Methods section, is the 
inclusion of meeting abstracts. This could be considered contro­
versial; however, to provide the most comprehensive scoping sys­
tematic review on this relatively “new” field of research in SAH, 
we thought it necessary to include these studies. Furthermore, 
many negative studies are presented at meeting venues, never 
reaching manuscript form. We wished to include any of these 
potential negative result abstracts to reduce publication bias 
seen within only positive studies. Yet, one must be cautioned in 
overinterpreting the results of the meeting abstracts. Given the 
nature of these publications, the quality of evidence is low and 
they are subject to significant reporting biases.
Second, within both the CMD and CSF reviews, some stud­
ies had missing data points, as seen within the tables. We made 
two distinct and separate attempts to contact the authors for 
information regarding these studies (i.e., missing demograph­
ics, etc.). The first was made in November 2016, with a second 
attempt in January 2017. Both were met with no response via 
electronic communication. Thus, we were unfortunately left with 
leaving these fields as “unknown” or “uncertain” within the tables. 
Although this is unfortunate, as the overall picture for each study 
may not be complete, this tends to be the nature of systematically 
conducted reviews within new and emerging areas of research.
Finally, the exact details on the cytokine measurements were 
not clearly delineated in most studies. With little comment on 
what was done to reduce interassay variability, as this could 
contribute to conflicting results seen within the review. Some 
mentioned use an enzyme­linked immunosorbent assay 
(ELISA) for the cytokine(s) of interest, while others mentioned 
multiplex “plates” for and array of cytokines, without further 
details. Furthermore, the timing of cytokine measurement was 
not mentioned or taken into consideration the reported studies. 
Thus, there is potential for normal circadian variation in cytokine 
profiles to have impacted the results reported.
CMD Cytokine Review
First, there were a small number of heterogenous studies found 
for the CMD review, with some manuscripts reporting on the 
same patient populations based on banked CMD samples. 
Furthermore, all included studies described heterogeneous 
cohorts of aneurysmal SAH patients with varying clinical/
radiographic admission grades and aneurysm locations, making 
summary interpretation of results difficult. Second, the ICU and 
surgical therapies received by these patients during CMD sample 
collection/processing was quite heterogeneous. Many studies 
failed to specify the therapies or protocols initialized within the 
ICU. These treatment variations may lead to substantial changes 
within the CMD cytokine measures. Thus, the described associa­
tions or “nil associations” may not be accurate given this potential 
confounder. Third, across all the studies, there was variation in 
CMD catheter location. This could impact the CMD cytokine 
measures obtained and the described relationships. In addition, 
the CMD perfusate, sampling frequency, use of pooled analysis, 
and cytokine panel/analytic platform employed varied between 
studies. Given this, it is impossible for us to directly compare 
the absolute values of cytokines and relative recovery. Thus, our 
reporting of the results for CMD in SAH is limited to purely 
descriptive. Fourth, complications associated with CMD moni­
toring were seldom reported. Given the total number of patients 
studied, it is unlikely that there were no patients suffering from 
complications of invasive monitoring. Finally, given the studies 
and results identified for the CMD review, there is likely a large 
publication bias, favoring only studies with positive results.
CSF Cytokine Review
First, there were many quite heterogeneous studies identified in 
the CSF cytokine review. The included papers varied by number 
of patients, admission clinical/radiographic grades, aneurysm 
location, aneurysm treatments (clipping vs. coiling), surgical 
interventions, ICU­based therapies offered/provided to patients, 
blinding during outcome assessment, primary outcome of the 
studies, and duration of follow­up. These limitations suggest 
caution when interpreting or generalizing the results of studies 
that describe relationships between CSF cytokine measures and 
patient outcomes. Second, many cytokine associations were 
selectively reported, making no reference to other CSF measures 
and the results of statistical analysis. Therefore, there may be many 
more “nil associations” that were not disclosed within the body of 
the manuscripts. Third, complication reporting was concerning 
within the literature identified (as mentioned above), with under­
reporting is suspected. Fourth, given all the above limitations and 
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heterogeneity issues, a meta­analysis was not performed. Finally, 
given the overwhelming number of “positive association” studies 
identified, the literature likely suffers from significant publication 
bias.
CMD Technical Considerations
The complexity involved in cytokine retrieval from CMD requires 
some brief comments regarding some potentially more “stand­
ardized” techniques. First, standard CMD catheters employ pore 
sizes between 20 and 100 kDa, as the goal with these devices is to 
measure “common” analytes such as glucose, glutamate, glycerol, 
lactate, and pyruvate. Although well designed for this purpose, 
they are ineffective for the retrieval or larger protein biomark­
ers, such as cytokines, where molecular weight can easily exceed 
these pore size. This it is critical to know the characteristics 
of the biomarker of interest, thus tailoring your CMD catheter 
to the biomarker (44). Second, the location of placement is key. 
Within the TBI literature, it has been well documented that CMD 
catheter placement in lesional vs. peri­lesional tissue yields very 
different profiles of “common” analyte retrieval (45). This has also 
been demonstrated within CMD cytokine profiles in TBI, with 
lesional/peri­lesional tissue expressing much high cytokine levels 
compared to healthy tissue (46, 47). Thus, we recommend place­
ment of the CMD catheter within the brain adjacent to a focal 
lesion or territory of interest. This way, the “at risk” brain would 
be monitored and not the irreversibly damaged areas. Third, 
the rate of perfusion should remain at 0.3μl/min. Higher perfu­
sion rates may impair the rate of uptake of these larger proteins 
(44), while there is not data to support improved recovery for 
lower rates. Fifth, the perfusate should be colloid based. Recent 
investigation into the type of perfusate has demonstrated that the 
relative rate of recovery for cytokines is improved with colloid 
perfusate over crystalloid (44). The exact colloid solution to use is 
currently unclear. Albumin solution appears to improve the rela­
tive recovery (44); however it is expensive and labor intensive to 
create, thus limiting its widespread applicability. Dextran­based 
solutions are another potential and have been applied within some 
of the SAH studies quoted within this review (14, 16). However, 
the literature surrounding the type of dextran solution to use is 
limited, and we cannot make any further definitive comments at 
this time. Sixth, it is unclear at the current time as to the impact of 
frequency of CMD measurement and pooling of samples. Given 
we do not currently have a clear idea of the temporal profile of 
cytokine changes in CMD fluid, we cannot give definitive recom­
mendations regarding the sampling frequency. Although, we 
would expect the rate of change in focal cytokine profile be on the 
order of hours or longer (such as 6 to 12 h). Finally, the cytokine 
analysis technique requires some comment and is applicable to 
both CMD and CSF analysis. Both ELISA and multiplex­based 
techniques have been described. All techniques are subject to 
inter­assay variability and thus should be conducted within estab­
lished laboratory settings with trained personal, comfortable with 
the employed technique. The use of ELISA vs. multiplex may be 
site dependent or study specific. Standard analytic techniques 
should be employed for multicenter collaborations to improved 
homogeneity in measurement technique. This also applied to the 
entire process of CMD or CSF sampling, storage, and analysis. 
In addition, the normal variation in cytokine profiles should be 
taken into account when determining sampling frequency and 
pooling samples for analysis. It is particularly important to ensure 
that between patients, the sampling frequency and employment 
of sample pooling is conducted in an identical manner. Circadian 
variation in cytokine profiles (48) could impact the interpreta­
tion of results, and thus, standardized sampling and pooling is 
a necessity.
Future Directions
Given the limited literature body and the recognized limitations 
in study design, there exists an opportunity for further research 
in the area of CMD and CSF cytokines in aneurysmal SAH, but 
these should seek to address the limitations seen in the studies 
included within the two systematic reviews. First, larger cohorts 
of aneurysmal SAH patients with predefined stratification of 
injury pattern are required. Heterogeneity in hemorrhage pat­
tern, clinical grade, and aneurysm location make the results of 
the above­mentioned studies difficult to interpret, even those 
with positive results. Large sample sizes may allow for clinical/
radiographic subgroup analysis and shed further light on the 
association of CMD/CSF cytokines with various subpopulations 
of aneurysmal SAH patients. While large studies undertaken with 
a uniform protocol would be ideal, we need to accept that these 
studies will often be conducted in relatively small populations of 
patients across several centers. Such a multiplicity of studies could 
be a substantial strength in exploring the pathophysiology and 
outcome associations of central nervous system cytokine levels 
across the spectrum of aSAH if we could undertake harmoniza­
tion of the studies. Consistency across multiple centers would 
require rigorous harmonization of studies, which would only be 
possible if there were clear data provided on disease character­
istics, catheter location, sample processing, and measurement 
techniques; and all studies used a common outcome assessment 
(e.g., GOSE at 3 months). With the application of common data 
elements between studies and centers, we may be able to more 
closely approach harmonization. Furthermore, banking of CSF 
and CMD samples from various SAH studies could prove to be a 
useful way of increasing the sample numbers required to analyze 
the milieu of CSF/CMD based cytokines. Second, homogeneous 
ICU/surgical treatments are necessary, preferably with protocol­
ized therapies. Including coiled and clipped patients within the 
same cohort of SAH patients assuredly confounds the associa­
tions between various measured cytokines and the described out­
comes. In addition, including patients with ICH evacuation and 
those undergoing DC due to malignant edema will also impact 
the resulting of cytokine measures. Third, with the application 
of CMD, catheter location must be considered during cytokine 
measures. Fourth, given the large number of cytokines involved, 
the use of principle component analysis of large patient popula­
tions with CMD and CSF cytokine measures may prove valuable. 
This has been applied within the TBI literature on CMD cytokines, 
with interesting preliminary results (49, 50). This could poten­
tially identify cytokine patterns of co­expression in CMD and 
CSF, highlighting targets for future studies and therapeutic inter­
vention. Fifth, accurate complication documentation is required. 
Sixth, one persistent problem may be the use of different analysis 
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platforms, which results in different measured concentrations. 
There are no easy solutions to this problem—although control 
plasma levels will provide some basis for harmonization, it will be 
difficult to get standardize levels in CSF and particularly in CMD. 
Finally, multicenter prospective evaluation of cytokines within 
CMD and CSF is necessary to improve patient recruitment and 
aid with spreading the substantial cost of cytokine analysis among 
centers. Without collaboration, single­center small studies may 
unfortunately fail to add to the existing literature.
CONCLUSiON
The evaluation of CMD and CSF cytokines is a new area of 
the literature in aneurysmal SAH. The two scoping systematic 
reviews demonstrated the following: (1) limited literature avail­
able on CMD cytokine measurement in aneurysmal SAH with 
some preliminary data supporting feasibility of measurement 
and potential association between IL­6 and patient outcome. (2) 
CSF levels of several cytokines may be associated with patient 
outcome at 3–6 months including IL­1ra, IL­6, IL­8, and TNF­a. 
(3) There is a small literature supporting an association between 
acute/subacute CSF TGF levels and the development of chronic 
hydrocephalus at 2–3  months. Given the preliminary nature 
of these data, further large prospective multicenter studies on 
cytokines in CMD and CSF need to be conducted.
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